DS Research is proud to be a participating site in Veradermics’ ongoing clinical trials evaluating VDPHL01, a first-in-class, non-hormonal oral treatment for androgenetic alopecia (pattern hair loss). These trials represent a significant step forward in addressing hair loss for both men and women. The Phase 2/3 study for male patients is a randomized, double-blind, placebo-controlled trial enrolling approximately 480 participants across 44 sites in the U.S., with a 13-month study duration. Simultaneously, a Phase 2 trial in female patients is underway, exploring safety and efficacy over a similar timeframe with both once- and twice-daily dosing regimens. DS Research’s involvement in these innovative studies reflects our commitment to advancing dermatologic science and bringing promising new therapies to patients affected by hair loss.